Ghost Tree Capital »

Acelyrin shares owned by Ghost Tree Capital

Quarter-by-quarter ownership of Acelyrin (SLRN) shares owned by Ghost Tree Capital from 13F filings

Historical chart of Ghost Tree Capital investment in Acelyrin

Tip: Access up to 7 years of quarterly data

All positions including Acelyrin held by Ghost Tree Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Acelyrin by Ghost Tree Capital

Quarter filed Position value Share count Share price at filing
2023-09-30 $4.1M 400k 10.17

More positions owned by Ghost Tree Capital

Moonlake Immunotherapeutics Class A Ord (MLTX)
Sarepta Therapeutics (SRPT)
Spdr Ser Tr S&p Biotech Call Option (XBI)
Akero Therapeutics (AKRO)
Krystal Biotech (KRYS)
Madrigal Pharmaceuticals (MDGL)
Tg Therapeutics (TGTX)
Immunovant (IMVT)
Ascendis Pharma A/s Sponsored Adr (ASND)
Axsome Therapeutics (AXSM)
Alpine Immune Sciences (ALPN)
Syndax Pharmaceuticals (SNDX)
Vaxcyte (PCVX)
Tarsus Pharmaceuticals (TARS)
Apellis Pharmaceuticals Call Option (APLS)

View all positions for Ghost Tree Capital

Top funds holding Acelyrin

Citadel Advisors
Vanguard Group
Opaleye Management
OrbiMed Advisors
venBio Partners
Jpmorgan Chase & Co
Artal Group
Samsara BioCapital
Ikarian Capital
Blue Owl Capital Holdings
Henderson Group
Decheng Capital
Logos Global Management
Kynam Capital Management
Goldman Sachs Group

View all funds holding Acelyrin